» Articles » PMID: 37274174

Hormonal Therapies in Females with Blood Disorders: Thrombophilia, Thrombosis, Hemoglobinopathies, and Anemias

Overview
Publisher Elsevier
Date 2023 Jun 5
PMID 37274174
Authors
Affiliations
Soon will be listed here.
Abstract

There is widespread use of gonadal steroid hormone therapy for a variety of indications throughout the reproductive and postreproductive lifespan. These therapies may have particular benefits and specific risk among those with blood disorders, including inherited or acquired bleeding disorders, thrombophilia, thrombosis, or anemia. This clinical review is intended to provide a guidance for counseling and management of adolescent and adult biologic females with thrombophilic risk factors and/or thrombosis who require hormonal therapy. In general, synthetic estrogens present in contraceptive products should be avoided in those with a personal or strong family history of thrombosis or thrombophilias. In contrast, natural estrogens present in formulations for climacteric symptom management do not need to be avoided, and vaginal or transdermal formulations are preferred. Likewise, transdermal estradiol is preferred for gender-affirming hormone therapy and requires individualized assessment in those at high risk of thrombosis. Progestogens (either synthetic progestins or naturally occurring progesterone) can be used safely in nearly all patients. There is minimal safety evidence among anticoagulated patients at risk for thrombosis, which requires a patient-specific approach when discussing hormone therapies.

Citing Articles

Acute Coronary Syndrome in Women: An Update.

Alder M, Adamek K, Lowenstern A, Raj L, Lindley K, Sutton N Curr Cardiol Rep. 2024; 26(5):293-301.

PMID: 38466532 PMC: 11450976. DOI: 10.1007/s11886-024-02033-6.


Progestin-only contraception is first line for sickle cell disease: a comment on "Hormonal therapies in females with blood disorders: thrombophilia, thrombosis, hemoglobinopathies, and anemias.".

Pecker L, Burke A, Streiff M, Lanzkron S, Naik R Res Pract Thromb Haemost. 2023; 7(6):102183.

PMID: 37711908 PMC: 10498431. DOI: 10.1016/j.rpth.2023.102183.

References
1.
Haddad L, Curtis K, Legardy-Williams J, Cwiak C, Jamieson D . Contraception for individuals with sickle cell disease: a systematic review of the literature. Contraception. 2011; 85(6):527-37. DOI: 10.1016/j.contraception.2011.10.008. View

2.
Pomp E, le Cessie S, Rosendaal F, Doggen C . Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol. 2007; 139(2):289-96. DOI: 10.1111/j.1365-2141.2007.06780.x. View

3.
Keenan L, Kerr T, Duane M, Van Gundy K . Systematic Review of Hormonal Contraception and Risk of Venous Thrombosis. Linacre Q. 2020; 85(4):470-477. PMC: 6322116. DOI: 10.1177/0024363918816683. View

4.
Sammaritano L . Contraception and preconception counseling in women with autoimmune disease. Best Pract Res Clin Obstet Gynaecol. 2019; 64:11-23. DOI: 10.1016/j.bpobgyn.2019.09.003. View

5.
Hennessy S, Berlin J, Kinman J, Margolis D, Marcus S, Strom B . Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis. Contraception. 2001; 64(2):125-33. DOI: 10.1016/s0010-7824(01)00234-7. View